Graft-versus-host disease cost-effectiveness of therapy: Difference between revisions

Jump to navigation Jump to search
Line 7: Line 7:


==Cost-Effectiveness of Therapy==
==Cost-Effectiveness of Therapy==
[[Corticosteroids]] are the most cost-effective therapy for GvHD. [[Prednisone]] and [[methylprednisolone]] are available at very low cost. If [[corticosteroids]] can be used, these should be given first. Second-line therapies such as alternative immunosuppresants are significantly more expensive. The most expensive therapies include biologics (such as antibodies) and [[cell-based therapies]] such as [[mesenchymal stem cell]] therapy.
[[Corticosteroids]] are the most cost-effective therapy for GvHD. [[Prednisone]] and [[methylprednisolone]] are available at very low cost. If [[corticosteroids]] can be used, these should be given first. Second-line therapies such as alternative immunosuppressants are significantly more expensive. The most expensive therapies include biologics (such as antibodies) and [[cell-based therapies]] such as [[mesenchymal stem cell]] therapy.


==References==
==References==

Revision as of 02:08, 5 July 2017

Graft-versus-host disease

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Graft-versus-host disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Graft-versus-host disease cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Graft-versus-host disease cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Graft-versus-host disease cost-effectiveness of therapy

CDC on Graft-versus-host disease cost-effectiveness of therapy

Graft-versus-host disease cost-effectiveness of therapy in the news

Blogs on Graft-versus-host disease cost-effectiveness of therapy

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Graft-versus-host disease cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]

Overview

Cost-effectiveness of therapy focuses on the use of balance of medical expenses and therapeutic efficacy. In the case of GvHD therapy, corticosteroids are the least expensive treatment option, and alternative immunosuppressants or biologics are more expensive.

Cost-Effectiveness of Therapy

Corticosteroids are the most cost-effective therapy for GvHD. Prednisone and methylprednisolone are available at very low cost. If corticosteroids can be used, these should be given first. Second-line therapies such as alternative immunosuppressants are significantly more expensive. The most expensive therapies include biologics (such as antibodies) and cell-based therapies such as mesenchymal stem cell therapy.

References